Abiopharma

HALOZYME THERAPEUTICS, INC. (HALO) Announces Business Combination HALOZYME THERAPEUTICS, INC. (HALO) has entered into a strategic transaction. Transaction Details:

• Target Company: billion in annual revenue. during his tenure, he delivered impressive financial results, leading large global teams across commercial operations, r&d, supply chain, and business development, and played a central role in major portfolio investments, restructuring initiatives, and business development transactions.earlier in his career, mr. snellgrove held cfo and senior finance leadership roles across pharmaceutical r&d, innovation, and m&a at johnson & johnson, as well as progressive finance roles at centocor prior to its
• Purchase Price: $50